4SC AG Entrate Q/Q

Cos'è Entrate Q/Q di 4SC AG?

Entrate Q/Q di 4SC AG è 1,135.54%

Qual è la definizione di Entrate Q/Q?

La crescita trimestrale dei ricavi, anno su anno , è l'aumento delle entrate di un'azienda rispetto alla performance nel corrispondente trimestre dell'anno precedente espresso in percentuale.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Entrate Q/Q di aziende nel Health Care settore su XETRA rispetto a 4SC AG

Cosa fa 4SC AG?

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.

Aziende con entrate q/q simili a 4SC AG